Program
AZD1390
Also written as “[11C]AZD1390”.
Its studies are mostly in Glioblastoma · Neoplasms, led by AstraZeneca.
Furthest: phase 1, since Jun 29, 20173 company-led studies, 1 open or runningNext primary completion: Apr 12, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 31 open or running | phase 1since Jun 29, 2017 | Jun 29, 2017 | Apr 12, 2028phase 1 · NCT07643870 |
- Named in AstraZeneca’s own pipeline as
AZD1390
, phase 1, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 29, 2017First study: phase 1 study in Healthy Volunteer Male SubjectsFirst studyNCT03215381 · 8 enrolled · Sweden
- Nov 28, 2017Phase 1 study in GlioblastomaNCT03423628 · 159 enrolled · United States, Japan, United Kingdom
- Dec 18, 2025Phase 1 study in NeoplasmsNCT07643870 · 8 planned · United Kingdom
Ahead
- Apr 12, 2028Primary completion: phase 1 study in NeoplasmsNCT07643870
TargetBeta
“An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, with potential antineoplastic activity. Upon oral administration, AZD1390 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activat…”NCIt, read by Claude
“An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, ”NCIt, by rule
Other programs on ATM
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ATM Inhibitor SYH2051rule | CSPC Pharmaceutical Group | phase 2 | 3 |
| TQB3117 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07643870Neoplasms · United Kingdom | 1 | Not yet recruiting | Apr 12, 2028 | 8 |
| NCT03423628Glioblastoma · United States, Japan, United Kingdom | 1 | Completed | Aug 31, 2026 | 159 |
| NCT03215381Healthy Volunteer Male Subjects · Sweden | 1 | Completed | Feb 19, 2018 | 8 |
How it is read
Names in the registry
- “AZD1390”, 4 entries
- “[11C]AZD1390”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.